A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
Key facts
- Who runs it
- AbbVie
- Where
- Boston, Chicago, Cincinnati, Louisville, Philadelphia, Pittsburgh, Portland, and Seattle, United StatesSee the 8 sitesAlso in 9 other countries, 27 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 124 people, planned
- Started
- 24 Jun 2019
- Expected to end
- Mar 2029
- Type of study
- Interventional, 5 groups
- Treatments tested
- Upadacitinib
- Record updated
- 3 August 2026
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participant have total body weight of 10 kg or higher at the time of screening
- Participant diagnosed with pcJIA (rheumatoid factor-positive or rheumatoid factor-negative polyarticular JIA, extended oligoarticular JIA, or systemic JIA with active arthritis and without active systemic features) with a history of arthritis affecting at least 5 joints within the first 6 months of disease (for extended oligoarticular JIA: <=4 joints within first 6 months of disease and >4 joints thereafter)
- Participant have 5 or more active joints at the time of screening, defined as the presence of swollen joints (not due to deformity) or, in the absence of swelling, joints with the limitation of movement (LOM) plus pain on motion and/or tenderness with palpitation, with LOM present in at least three of the active joints
- If receiving methotrexate (MTX), have been taking MTX for at least 12 weeks immediately before and including Study Day 1 on a stable dose of <=20 mg/m2 for at least 8 weeks before and including Study Day 1; in addition, participants should take either folic acid or folinic acid according to local standard of care
- If on oral glucocorticosteroids, must have been taking oral glucocorticosteroids at a stable dose (no greater than 10 mg/day or 0.2 mg/kg/day, whatever is lower) for at least 1 week before and including Study Day 1
Who cannot take part
- Participant have prior exposure to JAK inhibitor
- Participant with diagnosis of enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (JPSA)
Where in United States
Also in 9 other countries, 27 sites
- Boston Children's HospitalBoston, United States
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
- Cincinnati Childrens Hospital Medical CenterCincinnati, United States
- University of LouisvilleLouisville, United States
- The Children's Hospital of PhiladelphiaPhiladelphia, United States
- Children's Hospital of Pittsburgh of UPMCPittsburgh, United States
- Randall Children's HospitalPortland, United States
- Seattle Children's HospitalSeattle, United States
About the trial
What the trial wants to find out
This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of three parts: Part 1 is multiple-cohort study that consists of two sequential multiple dose groups. Participants benefiting from the study drug with no ongoing adverse events of special interest or serious adverse events will have option to enroll in Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability. Part 3 is an additional safety cohort to evaluate long-term safety and tolerability. Participants <18 years of age who are ongoing in Parts 2 and 3 will participate in an 104 week open-label extension of the study in Part 4.
The 5 groups in the trial
- Participants of age group 12 to <18 years receiving dose ATreatment being tested
Participants of age group 12 to \<18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
Treatment: Upadacitinib
- Participants of age group 12 to <18 years receiving dose BTreatment being tested
Participants of age group 12 to \<18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.
Treatment: Upadacitinib
- Participants of age group 6 to <12 years receiving dose ATreatment being tested
Participants of age group 6 to \<12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
Treatment: Upadacitinib
- Participants of age group 2 to <6 years receiving dose ATreatment being tested
Participants of age group 2 to \<6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
Treatment: Upadacitinib
- Participants of age group 2 to <18 years receiving dose ATreatment being tested
Participants of age group 2 to \<18 years administered with upadacitinib dose A as described in the protocol.
Treatment: Upadacitinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
- Record updated
- 3 August 2026